IDEXX Laboratories (IDXX)
NASDAQ: IDXX · Veterinary Diagnostics · Westbrook, ME
Our rating: Neutral
Neutral reaffirmed at $672.04, moderate conviction, November 3, 2026.
Breaks if: The neutral call turns cautious if revenue growth decelerates below 7% year-over-year for two consecutive reported quarters while the net margin slips below 22% — that combination would signal the franchise is losing pricing or volume leverage without a commensurate valuation reset. It turns positive if revenue growth re-accelerates above 15% for two straight quarters and the free-cash-flow yield expands above 2.5%, suggesting the multiple is starting to earn its keep rather than merely hold its ground.
Key figures
| Market value | $53.3B |
|---|---|
| Revenue, last 12 months | $4.7B |
| Net income, last 12 months | $1.2B |
| Free cash flow, last 12 months | $1.3B |
| Price to earnings | 45.1× |
| Free cash flow yield | 2.4% |
| Dividend yield | 0.0% |
| Operating margin | 32.3% |
| Return on equity | 68.9% |
| Beta to the S&P 500 | 0.89 |
| Volatility, annualized | 38.2% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $1.2B | 9.9% | $4.01 | $421M |
| June 30, 2026 | $1.2B | 9.7% | $4.27 | $323M |
| March 31, 2026 | $1.1B | 14.3% | $3.47 | $234M |
| December 31, 2025 | $1.1B | 14.3% | $3.09 | $326M |
| September 30, 2025 | $1.1B | 13.3% | $3.40 | $371M |
| June 30, 2025 | $1.1B | 10.6% | $3.63 | $152M |
| March 31, 2025 | $998M | 3.6% | $2.96 | $208M |
| December 31, 2024 | $954M | 5.8% | $2.62 | $233M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $1.22B: Claude 42%, Gemini 35%, Mistral 40%
- Diluted earnings per share are at least $3.09: Claude 78%, Gemini 95%, Mistral 90%
- Free cash flow for the quarter is at least $0.33B: Claude 68%, Gemini 65%, Mistral 60%
13 ledger entries and 38 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.